Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 3/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.42 |
| ▸ | CA1 | P00915 | 12/20 | 0.42 |
| ▸ | CA2 | P00918 | 12/20 | 0.42 |
| ▸ | CA4 | P22748 | 4/20 | 0.40 |
| ▸ | CA7 | P43166 | 4/20 | 0.40 |
| ▸ | CA9 | Q16790 | 7/20 | 0.39 |
| ▸ | CA12 | O43570 | 4/20 | 0.39 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.39 |
| ▸ | KDR | P35968 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3111561 | 0.90 | PTGS2 (0.46) | PTGS2PDPK1CA1CA2CA4 | |
| SCHEMBL3106885 | 0.83 | PTGS2 (0.45) | PTGS2PDPK1CA1CA2CA4 | |
| SCHEMBL13099967 | 0.83 | PTGS2 (0.51) | PTGS2PDPK1CA1CA2CA4 | |
| SCHEMBL3106373 | 0.83 | PTGS2 (0.48) | PTGS2PDPK1CA1CA2CA4 | |
| SCHEMBL3105400 | 0.82 | PTGS2 (0.45) | PTGS2PDPK1CA1CA2CA4 | |
| SCHEMBL13099971 | 0.81 | PTGS2 (0.48) | PTGS2PDPK1CA1CA2CA4 | |
| SCHEMBL3108950 | 0.79 | CA1 (0.51) | PTGS2CA1CA2CA4CA7 | |
| SCHEMBL3106233 | 0.79 | PTGS2 (0.47) | PTGS2PDPK1CA1CA2CA4 | |
| SCHEMBL3237230 | 0.79 | CA2 (0.55) | PTGS2CA1CA2CA4CA7 | |
| SCHEMBL3098272 | 0.79 | CA2 (0.47) | PTGS2PDPK1CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | AGOURON PHARMACEUTICALS, INC. | 2010-10-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100256357-A1 | HETEROCYCLES USEFUL AS INHIBITORS OF CARBONIC ANHYDRASE | CA2, CA7, CA9 | PTGS2 47/4885PDPK1 2124/4885CA1 7/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.